Principal Investigator
Leonel Hernandez Aya
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230532
Clinical Trial Summary
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647